Dear colleagues and EUGenMed friends!

There is ongoing progress in gender medicine. More and more researchers and doctors are interested in the topic, and the number of publications that investigate Sex and Gender (S&G) in medicine is steadily increasing. More and more journals are becoming interested in publishing S&G related studies, analysing clinical trials for gender-specific aspects.

The National Institutes of Health (NIH) of US recently organized a workshop assembling all reasons why S&G should be considered in medical investigations, in basic and clinical studies. The most prominent stakeholders in US participated and a number of important conclusions were made, http://ornl.od.nih.gov/news/scientificseminars.asp

Not only the NIH but also European funding agencies are considering S&G. The Berlin Institute of Health (BIH), a major research endeavour powered by the German Ministry of Research and Berlin Institutions is developing strategies to consider S&G in research and gender mainstreaming in its funding policy. https://www.bihealth.org/en

The EUGenMed project is making headway in promoting S&G in research and creating awareness among different stakeholders. You will find the report from our kick-off conference under “News” on our website. It can offer a glimpse at the discussions at the kick-off conference, the broad spectrum of European Stakeholders in gender medicine, who contributed to S&G at our conference and how positive the attitude of the European Commission was.

Milestone 3 will be reached in the very near future: we are organising 4 workshops as planned in our project - see middle column. We feel that this is an extraordinary project and great progress in European gender medicine. Please stay tuned and participate in our activities!

Prof. Dr. med. Dr. h.c. Vera Regitz-Zagrosek
http://www.eugenmed.eu/
EUGenMed Coordinator; Director of the Institute for Gender in Medicine (GIM) at Charité - Universitätsmedizin Berlin

Workshop 1: “Sex and gender in clinical medicine and clinical pharmacology”

The 1st workshop (WS) is organized by Sabine Oertelt-Prigione and Vera Regitz-Zagrosek, Charité Berlin, 1-2 December 2014. A group of 25 experts has been invited to generate a white paper focusing on guideline relevant sex and gender (S&G) information in cardiovascular diseases, and their comorbidities and management. Furthermore, policy briefs on relevant clinical topics will be reviewed and a slide set on S&G aspects in health and clinical medicine for official presentations to non-expert audiences will be generated. A number of materials is being prepared for this workshop and we are looking forward to an exciting discussion.

Workshop 2: “Sex and Gender in public health and prevention”

The 2nd WS will take place on 2-3 February 2015 in Maastricht, the Netherlands, chaired by Ineke Klinge and Elisabeth Zemp Stutz. This was organized with support from Lucie Dalibert, Sabine Oertelt-Prigione, and Petra Verdonk. The focus will be S&G risk factors for non-communicable diseases (NCDs) across Europe. NCDs such as cardiovascular disease (CVD), cancer and diabetes are the leading cause of death in the world today. We will assemble the existing and evidence-based knowledge concerning S&G aspects of risk factors for NCDs with a focus on cardiovascular disease. Furthermore we will discuss and identify current gaps concerning S&G aspects and strategies for implementing the available knowledge.

Workshop 3: “Basic biomedical research, preclinical drug development”

The 3rd workshop will be organized on 16-17 February 2015 in Berlin by Ute Seeland and Vera Regitz-Zagrosek. Main topics will be epigenetic and genetic mechanisms of S&G differences, sex and gender aspects in the developmental origin of diseases, sex specific mechanism in cellular signalling and function and S&G aspects in preclinical drug development.

Workshop 4: “Medicines Regulation and Medical Education”

The 4th WS will be organized by EIWH, at 2-3 March 2015 in Brussels. Topics of this workshop will be S&G aspects in drug regulation in the assessment of sex specific effects and adverse effects. In the second part of this workshop we will discuss S&G aspects in medical education.

Zuhai Kartal, B.A., recently joined our office at Charité - Universitätsmedizin Berlin as a project assistant. She holds a Bachelor’s degree in Public Management, and also obtained a traineeship as a bilingual assistant in the languages English and Spanish. She has worked both for profit and non-profit organisations for several years.

Carola Schubert, MD, PhD, is the study manager of the GIM at Charité - Universitätsmedizin Berlin. She is organising all administrative aspects of this project. Carola Schubert holds a PhD in Biology and has additional training as a study manager. She is also study manager in a European Integrated Training Network (RADOX) and in the German Centre for Cardiovascular diseases (DZHK) in Berlin.

Ineke Klinge, Associate Professor of Gender Medicine at Maastricht University, is a partner right from the beginning but she has now obtained a new and very important role: She has been nominated as the chair of the Horizon 2020 Advisory Group on Gender (AGG). This was created in February 2014. It brings together the gender experts participating in each part or domain of Horizon 2020. Mandate of the AGG is to provide advice to the Commission services on integration of the gender dimension in upcoming work programmes, http://ec.europa.eu/transparency/regexpert/index.cfm?do=introDetail.groupDetail&groupID=3034

Upcoming workshops & Final conference

01.-02.12.14 WS 1, Sex and gender in clinical medicine and clinical pharmacology. Berlin (Germany)
02.-03.02.15 WS 2, Sex and Gender in public health and prevention. Maastricht (the Netherlands)
16.-17.02.15 WS 3, Basic biomedical research, preclinical drug development. Berlin (Germany)
02.-03.03.15 WS 4, Medicines Regulation and Medical Education (WS2). Brussels (Belgium)
July 2015 Final conference - Presentation of the Roadmap Brussels (Belgium)

This project the European Gender Medicine Network (EUGenMed) has received funding from the European Union’s Seventh Framework Programme for research, technological development and demonstration under grant agreement No. 602050.